Safety and Tolerability Demonstrated Over 48 Weeks
Includes adverse reactions at least possibly, probably, or very likely to be related to the drug. Intensities are defined as follows: moderate (discomfort enough to cause interference with usual activity); severe (incapacitating with inability to do work or usual activity).
Low rates of discontinuation due to treatment-emergent ADRs at Week 481
- 5.2% and 2.6% in patients receiving INTELENCE® (etravirine) + BR* vs placebo + BR, respectively
Please see full description of study design and baseline characteristics.
ADR=Adverse drug reaction.
*The BR for INTELENCE® and placebo arms consisted of darunavir/ritonavir + ≥2 other investigator-selected ARVs (N[t]RTIs ± ENF). In the INTELENCE® arm (n=599), 25.5% of patients used ENF de novo and 20.0% reused ENF. In the placebo arm (n=604), 26.5% of patients used ENF de novo and 20.4% reused ENF.